Organogenesis Holdings Inc.
NASDAQ:ORGODrug Manufacturers - Specialty & Generic
+$0.08 today
- Market cap
- $110.75M
- Beta
- 1.33
- P/E (TTM)
- -1086.7
- EPS (TTM)
- -$0.00
Volume 0.86M
Average 1.49M
ORGO Accounts Receivables
Cash effect of the change in amounts owed by customers; growing receivables consume cash.
Organogenesis Holdings Inc.NASDAQ: ORGO
Accounts Receivables · Q1 FY2026 · quarter ended Mar 2026
Accounts receivables growth accelerates
Q1 FY2026 accounts receivables of $104.5M rose 1743.7% year over year, ahead of the +54.1% change in trailing-twelve-month accounts receivables. Over 3 fiscal years it compounded at +136.4% a year.
Context
- Accounts receivables amounted to 20.6% of revenue in FY2025, up 14.0 pp from a year earlier.
- Accounts receivables increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +1743.7% holds above the trailing-twelve-month pace of +54.1%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Receivables history
USD · from the cash flow
- Latest · FY2025
- (115.8M) USD
- Year-over-year change
- -264.2%
| Period | Period end | Accounts Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (115.8M) | -264.2% |
| FY2024 | 2024-12-31 | (31.8M) | -674.1% |
| FY2023 | 2023-12-31 | 5.54M | +163.2% |
| FY2022 | 2022-12-31 | (8.77M) | +71.0% |
| FY2021 | 2021-12-31 | (30.23M) | — |
Accounts Receivables vs competitors
How ORGO compares with its peers on the latest reported figures
- Peers report in different currencies, so accounts receivables is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +54.1% is the 3rd highest of 8, against a peer median of -75.5%.
- Accounts receivables amounts to 3.3% of revenue for ORGO, versus a peer median of 2.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $59.9M USD | +225.6% | -40.0% | 8.9% | |
| LTM Mar 2026 | $51.06M USD | +91.4% | +77.2% | 12.2% | |
| LTM Mar 2026 | $16.97M USD | +54.1% | +136.4% | 3.3% | |
| LTM Mar 2026 | $8.53M USD | -48.4% | +7.0% | 2.8% | |
| LTM Apr 2026 | $3.7M USD | -169.8% | — | 0.4% | |
| LTM Mar 2026 | $3.41M USD | -86.4% | — | 5.4% | |
| LTM Mar 2026 | $2.68M USD | -75.5% | -22.4% | 2.9% | |
| LTM Feb 2026 | $2.4M USD | -146.8% | — | 0.8% | |
| LTM Mar 2026 | $0 USD | — | — | — | |
| LTM Mar 2026 | CA$0 CAD | — | — | 0.0% | |
| LTM Mar 2026 | $0 USD | — | — | — | |
| Peer median (excluding ORGO) | — | -75.5% | -7.7% | 2.8% | |
Competitors are the stored peer set for ORGO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 94.9M | 15.53M | 4.95M | 861K | 37.03M |
| Depreciation & Amortization | 16.68M | 10.73M | 23.45M | 17.03M | 26.94M |
| Deferred Income Tax | (31.98M) | 1.98M | 2.01M | (10.72M) | 9.5M |
| Stock-Based Compensation | 3.86M | 6.55M | 9M | 10.58M | 13.3M |
| Change in Working Capital | (39.29M) | (34.08M) | (18.07M) | (48.89M) | (132.38M) |
| Accounts Receivables | (30.23M) | (8.77M) | 5.54M | (31.8M) | (115.8M) |
| Inventory | (9.3M) | (9.41M) | 6.58M | (6.2M) | (17.92M) |
| Accounts Payables | 3.85M | 3.26M | (108K) | (2.37M) | (528K) |
| Other Working Capital | (3.6M) | (19.16M) | (30.08M) | (8.51M) | 1.87M |
| Other Non-Cash Items | 17.8M | 24.15M | 9.59M | 45.35M | 35.3M |
| Operating Cash Flow | 61.98M | 24.86M | 30.92M | 14.21M | (10.31M) |
| Capital Expenditures | (31.22M) | (33.9M) | (24.36M) | (10.03M) | (14.15M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (31.22M) | (33.9M) | (24.36M) | (10.03M) | (14.15M) |
| Debt Repayment | (2.01M) | (3.01M) | (5.17M) | (67.64M) | (1.17M) |
| Common Stock Issued | 2.2M | 0 | 0 | 0 | 157K |
| Common Stock Repurchased | 0 | 0 | 0 | (25.48M) | 0 |
| Dividends Paid | 0 | 0 | 0 | (1.8M) | 0 |
| Other Financing Activities | (1.22M) | 814K | (332K) | 1.87M | (16.35M) |
| Financing Cash Flow | (1.04M) | (2.2M) | (5.51M) | 27.64M | (17.36M) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 29.72M | (11.24M) | 1.05M | 31.81M | (41.82M) |
| Free Cash Flow | 30.76M | (9.04M) | 6.55M | 4.18M | (24.46M) |
Organogenesis Holdings Inc.
NASDAQ:ORGO
Intrinsic Alpha fair value
Locked
Current Price
$0.85
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.